Checked against the statute, not against other trackers.
Or start with what the evidence showsThe honest answer differs enormously depending on which one you came for.
Strongest evidence
The best-designed trial in the field is in alcohol use disorder, not depression: 95 participants, double-blind, with an active placebo rather than an inert one, showing heavy drinking days of 9.7% against 23.6% over 32 weeks.
Read the evidencePromising, and widely overstated
Two Phase 3 trials of synthetic psilocybin met their primary endpoints in 2025 and 2026, with modest differences of 3.6 and 3.8 MADRS points. The most-quoted trial in the field — psilocybin versus escitalopram — did not meet its primary endpoint.
Read the evidenceEarly and exploratory
Psilocin acts primarily at the serotonin 5-HT2A receptor, and imaging studies report changes in brain connectivity and structure that outlast the acute effects. The mechanism by which any of this would produce durable clinical benefit is not established.
Read the evidenceNo published trial data
There is no published clinical trial data on psilocybin for PTSD. The US Department of Veterans Affairs states this plainly, and neither psilocybin nor MDMA appears in the VA/DoD Clinical Practice Guideline for PTSD.
Read the evidenceEach opens onto a dataset we maintain, carrying the date we last checked it against the source.
The law
Reviewed August 30, 20262of 51 jurisdictionsallow legal supervised access
All 50 states and DC, with the statute, the local ordinances and the penalties. We name the states other trackers get wrong.
The evidence
Reviewed August 31, 20261of 4 conditionshas evidence we call strong
Every trial with its design, its size, its comparator and its limitation in the same row. Including the ones whose results cut against psilocybin.
Taking part
Reviewed August 31, 202643of 133 trialsmake you stop your psychiatric medication first
Every study recruiting right now, pulled from ClinicalTrials.gov, with the eligibility terms the registry states in language you have to be a researcher to parse.
Checked against the paper
All three come from coverage citing real studies. All three get the study backwards.
Reported
“Psilocybin beat escitalopram for depression.”
The paper says
The trial missed its main outcome — p=0.17. The figures people quote are unadjusted secondary numbers, and the authors say no clinical conclusions follow from them.
Reported
“SSRIs block psilocybin, so taper first.”
The paper says
Two weeks on escitalopram left mood and mystical-type experience unchanged. A 2024 analysis found the edge vanished among people who had recently stopped. The taper tracked the worse outcome, not the drug.
Reported
“The FDA is about to approve psilocybin.”
The paper says
Priority vouchers cut review to one or two months. A faster review is still a review. Trigger laws wait on FDA approval and DEA rescheduling — both.
Pulled from ClinicalTrials.gov and filtered to studies still recruiting. Every entry says whether you have to come off your psychiatric medication first — the requirement that rules out more people than anything else.